{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:08:18Z","timestamp":1777662498628,"version":"3.51.4"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/mnm.0b013e32834cecfe","type":"journal-article","created":{"date-parts":[[2011,10,15]],"date-time":"2011-10-15T09:26:55Z","timestamp":1318670815000},"page":"69-79","source":"Crossref","is-referenced-by-count":12,"title":["Specificity and sensitivity of 99mTc-EDDA\/HYNIC-Tyr3-octreotide (99mTc-TOC) for imaging neuroendocrine tumors"],"prefix":"10.1097","volume":"33","author":[{"given":"Jes\u00fas","family":"Sep\u00falveda-M\u00e9ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consuelo Arteaga","family":"de Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Pedraza-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Murphy-Stack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Rojas-Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofelia","family":"Gonz\u00e1lez-Trevi\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"Suppl 1","key":"R1-10-20210212","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000051851","article-title":"Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors.","volume":"62","author":"Rindi","year":"2000","journal-title":"Digestion"},{"key":"R2-10-20210212","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours.","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"issue":"Suppl 7","key":"R3-10-20210212","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mdq290","article-title":"Gastrointestinal neuroendocrine tumors.","volume":"21","author":"Oberg","year":"2010","journal-title":"Ann Oncol"},{"key":"R4-10-20210212","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11894-010-0158-4","article-title":"Clinical perspective on gastric neuroendocrine neoplasia.","volume":"13","author":"Lawrence","year":"2011","journal-title":"Curr Gastroenterol Rep"},{"key":"R5-10-20210212","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MPA.0b013e3181f94cc4","article-title":"Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region.","volume":"40","author":"Wang","year":"2011","journal-title":"Pancreas"},{"key":"R6-10-20210212","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1210\/jcem-65-6-1127","article-title":"Hormones producing gastrointestinal tumors contain a high density of somatostatin receptors.","volume":"65","author":"Reubi","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-10-20210212","first-page":"471","article-title":"Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance.","volume":"70","author":"Reubi","year":"1997","journal-title":"Yale J Biol Med"},{"key":"R8-10-20210212","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1056\/NEJM199011013231805","article-title":"Somatostatin receptor imaging in the localization of endocrine tumors.","volume":"323","author":"Lamberts","year":"1990","journal-title":"N Engl J Med"},{"key":"R10-10-20210212","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.semnuclmed.2006.03.007","article-title":"Imaging of neuroendocrine tumors.","volume":"36","author":"Rufini","year":"2006","journal-title":"Semin Nucl Med"},{"key":"R11-10-20210212","first-page":"87","article-title":"Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.","volume":"31","author":"Bal","year":"2010","journal-title":"Trop Gastroenterol"},{"key":"R12-10-20210212","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1102\/1470-7330.2010.9007","article-title":"Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.","volume":"10","author":"Hicks","year":"2010","journal-title":"Cancer Imaging"},{"key":"R13-10-20210212","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s002590050314","article-title":"Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.","volume":"25","author":"Chiti","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"R14-10-20210212","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.gie.2010.08.030","article-title":"EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors.","volume":"73","author":"Kashab","year":"2011","journal-title":"Gastrointest Endosc"},{"key":"R15-10-20210212","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe1- and 123I- Tyr3-octreotide: the Rotterdam experience with more than 1000 patients.","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"key":"R16-10-20210212","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0001-2998(95)80014-X","article-title":"Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).","volume":"25","author":"Olsen","year":"1995","journal-title":"Semin Nucl Med"},{"key":"R17-10-20210212","first-page":"542","article-title":"Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.","volume":"36","author":"Jamar","year":"1995","journal-title":"J Nucl Med"},{"key":"R18-10-20210212","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1385\/ENDO:20:3:307","article-title":"Octreoscan radioreceptor imaging.","volume":"20","author":"Van der Lely","year":"2003","journal-title":"Endocrine"},{"key":"R19-10-20210212","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00259-010-1473-6","article-title":"111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Oncology Committee of the EANM.","volume":"37","author":"Bombardieri","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-10-20210212","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","article-title":"The impact of 68Ga-DOTATOC positron emission tomographycomputed tomography on the multimodal management of patients with neuroendocrine tumors.","volume":"252","author":"Frilling","year":"2010","journal-title":"Ann Surg"},{"key":"R22-10-20210212","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MNM.0b013e3283412143","article-title":"18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.","volume":"32","author":"Giammarile","year":"2011","journal-title":"Nucl Med Commun"},{"key":"R23-10-20210212","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00259-005-0006-1","article-title":"Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.","volume":"33","author":"Koukouraki","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R24-10-20210212","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of 90Y-DOTA-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"R25-10-20210212","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1007\/s00259-009-1151-8","article-title":"Effects of therapy with 177Lu-DOTA 0,Tyr 3octreotate on endocrine function.","volume":"36","author":"Teunissen","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-10-20210212","first-page":"24","article-title":"Comparative analysis of 99mTc-depreotide and 99mTc-EDDAHYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules.","volume":"9","author":"Plachcinska","year":"2006","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"R27-10-20210212","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1021\/bc980121c","article-title":"Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and Tyr3octreotide.","volume":"10","author":"Decristoforo","year":"1999","journal-title":"Bioconjug Chem"},{"key":"R28-10-20210212","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s002590050556","article-title":"Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.","volume":"27","author":"Bangard","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"R29-10-20210212","first-page":"1114","article-title":"99mTc-HYNIC-Tyr3-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.","volume":"41","author":"Decristoforo","year":"2000","journal-title":"J Nucl Med"},{"key":"R30-10-20210212","first-page":"708","article-title":"An intrapatient comparison of 99mTc-EDDAHYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.","volume":"44","author":"Gabriel","year":"2003","journal-title":"J Nucl Med"},{"key":"R32-10-20210212","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe1- and 123I- Tyr3-octreotide: the Rotterdam experience with more than 1000 patients.","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"key":"R33-10-20210212","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jlcr.672","article-title":"Preparation via coligand exchange and characterization of 99mTc-EDDA-HYNIC-D-Phen1-Tyr3octereotide(99mTc-EDDAHYNIC- TOC).","volume":"46","author":"Von Guggenberg","year":"2003","journal-title":"J Labelled Cpd Radiopharm"},{"key":"R34-10-20210212","first-page":"237","article-title":"99mTc-EDDAHYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors.","volume":"49","author":"Gabriel","year":"2005","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R35-10-20210212","first-page":"35","article-title":"99mTc-EDDAHYNIC-TOC somatostatin receptor scintigraphy in daily clinical practice.","volume":"16","author":"Chrapko","year":"2010","journal-title":"Med Sci Monit"},{"key":"R36-10-20210212","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MNM.0b013e32834508b3","article-title":"Evaluation of somatostatin receptors in large cell pulmonary neuroendocrine carcinoma with 99mTc-EDDAHYNIC-TOC scintigraphy.","volume":"32","author":"Nocun","year":"2011","journal-title":"Nucl Med Commun"},{"key":"R37-10-20210212","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1210\/jcem.84.2.5497","article-title":"Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors.","volume":"84","author":"Hofland","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R38-10-20210212","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10571-010-9587-8","article-title":"Chromogranin A and the tumor microenvironment.","volume":"30","author":"Corti","year":"2010","journal-title":"Cell Mol Neurobiol"},{"key":"R40-10-20210212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ecl.2010.12.001","article-title":"The clinical relevance of chromogranin a as a biomarker for gastroenteropancreatic neuroendocrine tumors.","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R41-10-20210212","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s13277-010-0104-y","article-title":"CD117, Ki-67, and p53 predict survival in neuroendocrine carcinomas, but not within the subgroup of small cell lung carcinoma.","volume":"32","author":"Erler","year":"2011","journal-title":"Tumour Biol"},{"key":"R42-10-20210212","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.beem.2006.12.002","article-title":"Biochemistry of neuroendocrine tumours.","volume":"21","author":"de Herder","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R43-10-20210212","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.apradiso.2006.01.015","article-title":"Biokinetics and dosimetry in patients of 99mTc-EDDAHYNIC-Tyr3-octreotide prepared from lyophilized kits.","volume":"64","author":"Gonzalez-Vazquez","year":"2006","journal-title":"Appl Radiat Isot"},{"key":"R44-10-20210212","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/jps.20148","article-title":"Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of 99mTc-EDDA-HYNIC-D-phe1, Tyr3-octreotide, a somatostatin analog for tumor diagnosis.","volume":"93","author":"von Guggenberg","year":"2004","journal-title":"J Pharm Sci"},{"key":"R45-10-20210212","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.3748\/wjg.14.5377","article-title":"Neuroendocrine tumors of the gastro-entero-pancreatic system.","volume":"14","author":"Massironi","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"Suppl 1","key":"R46-10-20210212","first-page":"S20","article-title":"Clinicopathologic aspects of gastric neuroendocrine tumors.","volume":"19","author":"Rindi","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"R47-10-20210212","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/ajg.2010.341","article-title":"Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971.","volume":"105","author":"Ellis","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R50-10-20210212","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ecl.2010.12.002","article-title":"Standard imaging techniques for neuroendocrine tumors.","volume":"40","author":"Bushnell","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R51-10-20210212","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.crad.2007.11.008","article-title":"The role of hybrid SPECT-CT in oncology: current and emerging clinical applications.","volume":"63","author":"Chowdhury","year":"2008","journal-title":"Clin Radiol"},{"key":"R52-10-20210212","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00259-010-1390-8","article-title":"A review on the clinical uses of SPECTCT.","volume":"37","author":"Mariani","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R53-10-20210212","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11102-006-0270-5","article-title":"Somatostatin receptor imaging for neuroendocrine tumors.","volume":"9","author":"de Herder","year":"2006","journal-title":"Pituitary"},{"key":"R54-10-20210212","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0026-0495(90)90217-Z","article-title":"Distribution of somatostatin receptor in normal and tumour tissue.","volume":"30","author":"Reubi","year":"1990","journal-title":"Metabolism"},{"key":"R55-10-20210212","first-page":"24","article-title":"The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology.","volume":"54","author":"Cascini","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R56-10-20210212","first-page":"41","article-title":"Less frequent requests for In-111 pentreotide and its brothers of endocrinological interest.","volume":"36","author":"Cuccurullo","year":"2011","journal-title":"Minerva Endocrinol"},{"key":"R57-10-20210212","first-page":"708","article-title":"An intrapatient comparison of 99mTc-EDDAHYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.","volume":"44","author":"Gabriel","year":"2003","journal-title":"J Nucl Med"},{"key":"R58-10-20210212","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.mcg.0000212640.52359.ca","article-title":"OctreoScan positive Crohns disease mimicking an ileal carcinoid tumor.","volume":"42","author":"Marko","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"R59-10-20210212","first-page":"1281","article-title":"Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis.","volume":"47","author":"Lebtahi","year":"2006","journal-title":"J Nucl Med"},{"key":"R60-10-20210212","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.surg.2004.06.057","article-title":"Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment.","volume":"136","author":"Norton","year":"2004","journal-title":"Surgery"},{"key":"R61-10-20210212","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00000658-199808000-00013","article-title":"Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome.","volume":"228","author":"Alexander","year":"1998","journal-title":"Ann Surg"},{"key":"R62-10-20210212","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.5858\/2009-0165-RSR2.1","article-title":"Merkel cell carcinoma.","volume":"134","author":"Wong","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"R63-10-20210212","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/BF03026821","article-title":"Visualization of gallbladder with In-111 labeled octreotide in post prandial state.","volume":"20","author":"Gedik","year":"2006","journal-title":"Ann Nucl Med"},{"key":"R64-10-20210212","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00259-007-0479-1","article-title":"Somatostatin receptor scintigraphy using 99mTc-EDDAHYNIC-TOC in patients with medullary thyroid carcinoma.","volume":"34","author":"Czepczynski","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R65-10-20210212","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/BF03349233","article-title":"Somatostatin receptor scintigraphy in thoracic diseases.","volume":"30","author":"Ameri","year":"2007","journal-title":"J Endocrinol Invest"},{"key":"R66-10-20210212","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00259-006-0117-3","article-title":"Differential diagnosis of solitary pulmonary nodules based on 99mTc-EDDAHYNIC-TOC scintigraphy: the effect of tumour size on the optimal method of image assessment.","volume":"33","author":"Plachcinska","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0b013e32834cecfe","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:42:15Z","timestamp":1620963735000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006231-201201000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0b013e32834cecfe","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}